Citius Pharmaceuticals, Inc. (CTXR) — Financial statements
Income statement, balance sheet, and cash flow for Citius Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.21↑2.2% | 0.21↑7.9% | 0.19↑8.1% | 0.18↑9.0% | 0.16 | |
| Gross Profit | -0.21↓2.2% | -0.21↓7.9% | -0.19↓8.1% | -0.18↓9.0% | -0.16 | |
| Operating Expenses | ||||||
| R&D Expenses | 9↓23.1% | 12↓19.7% | 15↓16.1% | 18↑44.2% | 12 | |
| General & Administrative Expenses | 19↑1.6% | 18↓16.7% | 22↑39.9% | 16↑38.7% | 11 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 19↑1.6% | 18↓16.7% | 22↑39.9% | 16↑38.7% | 11 | |
| Other Expenses | 11↓10.3% | 12 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 38↓8.8% | 42↑14.3% | 37↑10.3% | 33↑41.6% | 24 | |
| Total Costs & Expenses | 39↓8.3% | 42↑14.3% | 37↑10.3% | 33↑41.6% | 24 | |
| Operating Results | ||||||
| Operating Income | -39↑8.3% | -42↓14.3% | -37↓10.3% | -33↓41.6% | -24 | |
| Depreciation & Amortization | 0.21↑2.2% | 0.21↑7.9% | 0.19↑8.1% | 0.18↑9.0% | 0.16 | |
| EBITDA | -38↑1.1% | -39↓21.6% | -32↑3.4% | -33↓43.7% | -23 | |
| EBIT | -38↑1.1% | -39↓21.5% | -32↑3.3% | -33↓43.5% | -23 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.16↓120.8% | 0.76↓35.7% | 1 | 0.00↓100.0% | 0.25 | |
| Interest Income | 0.11↓85.5% | 0.76↓35.7% | 1↑369.1% | 0.25↓4.0% | 0.26 | |
| Interest Expense | 0.27 | 0.00 | 0.00↓100.0% | 0.25↑2219.4% | 0.01 | |
| Non-Operating Income | -0.11↑96.5% | -3↑34.0% | -5↓1795.4% | -0.25↑48.5% | -0.49 | |
| Other Income / Expenses | -0.16↓105.0% | 3↓34.0% | 5↑1795.4% | 0.25↓47.3% | 0.48 | |
| Income Before Tax | -39↑0.4% | -39↓21.5% | -32↑3.3% | -33↓43.4% | -23 | |
| Income Tax Expense | 1↑83.5% | 0.58↑0.0% | 0.58↑0.0% | 0.58 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -40↓0.8% | -39↓21.2% | -33↑3.3% | -34↓45.9% | -23 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -37↑4.4% | -39↓20.3% | -33↑3.3% | -34↓45.5% | -23 | |
| Bottom-Line Net Income | -37↑6.8% | -40↓19.3% | -34↓0.2% | -34↓37.3% | -25 | |
| EPS (Basic) | -3.38↑43.4% | -5.97↓7.2% | -5.57↑3.3% | -5.76↓2.1% | -5.64 | |
| EPS (Diluted) | -3.38↑43.4% | -5.97↓7.2% | -5.57↑3.3% | -5.76↓2.1% | -5.64 | |
| Weighted Average Shares | 11↓4.5% | 12↑19.0% | 10↑0.0% | 10↑34.5% | 7 | |
| Weighted Average Diluted Shares | 11↓4.5% | 12↑14.9% | 10↑3.6% | 10↑34.5% | 7 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.